SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Bullish on SIGA ...
SIGA
|
|
|
+32.87%
in
228 days
engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases. It focuses on products for use in defense against biological warfare agents, such as smallpox and arenaviruses/hemorrhagic fevers. Its products include ST-246, an orally administered anti-viral drug targets smallpox virus; and ST-294, which demonstrates antiviral activity in cell culture assays against arenavirus pathogens. The companyÂ’s antiviral products, which are in various stages of development ranging from initial ...
|
Siga is a buy
SIGA
|
|
|
+82.11%
in
975 days
Just wanna buy back
|
SIGA is going to fly
SIGA
|
|
|
+21.14%
in
52 days
(closed on 03/28/07)
Siga's smallpox drug granted Orphan Drug status by FDA
<>
<>SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses. It discovers vaccines and pharmaceutical agents to fight pathogens. The company primarily develops the SIGA-246, an orally administered antiviral drug that targets the smallpox virus. SIGA Technologies also has antiviral programs targeting other Category A viral pathogens, including arenaviruses, lymphocytic choriomeningitis vi...
|
SIGA is going to fly
SIGA
|
|
|
+21.14%
in
52 days
(closed on 03/28/07)
Siga's smallpox drug granted Orphan Drug status by FDA
<>
<>SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses. It discovers vaccines and pharmaceutical agents to fight pathogens. The company primarily develops the SIGA-246, an orally administered antiviral drug that targets the smallpox virus. SIGA Technologies also has antiviral programs targeting other Category A viral pathogens, including arenaviruses, lymphocytic choriomeningitis vi...
|
SIGA is going to fly
SIGA
|
|
|
+21.14%
in
52 days
(closed on 03/28/07)
Siga's smallpox drug granted Orphan Drug status by FDA
<>
<>SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses. It discovers vaccines and pharmaceutical agents to fight pathogens. The company primarily develops the SIGA-246, an orally administered antiviral drug that targets the smallpox virus. SIGA Technologies also has antiviral programs targeting other Category A viral pathogens, including arenaviruses, lymphocytic choriomeningitis vi...
|
From the Blogosphere
SIGA Shares Could Double on Pending Government News
<>BioMedReports has learned that shares of this bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses is expecting big news and government orders.
Our Subscribers were alerted Monday that a series of big government orders are anticipated to be announced "any day now," after sources confirmed to us that the official news and first purchase order could come within days.
SIGA Technologies, Inc. (NASDAQ:SIGA) has been trading up since late Thursday, when funds and others who...
|
Short Covering on Siga's Big News Makes for Happy Holidays
Shares of Siga Technologies, Inc. (SIGA) broke the eight dollar mark Tuesday afternoon on anticipation of the possibility that some big government orders could be imminent.
BioMedReports issued a mid-day trade alert on Tuesday, alerting readers that the recent price action of the SIGA stock could indicate that news is pending.
|
SIGA Technologies Inc. (SIGA) Posts Positive Q2 Results; Attributes Smallpox Treatment and Strategic Relationships to Success
|
|
|
SIGA Technologies Inc. (Nasdaq: SIGA) applies viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases. The company focuses on utilizing these products for biological warfare defense. The company today announced its second-quarter results for 2008, posting positive results due to its continued research and manufacturing efforts. <>SIGA recognized grants and contracts totaling $1.7 million for the period ended June 30, 2008, up 19 percent compared to the second quarter o...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on SIGA |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About SIGA Technologies Inc.
- Answers.com
